GLP-1 Receptor Agonist Market Growth Accelerated By Expanding Patient Base

GLP-1 Receptor Agonist Market


GLP-1 receptor agonists are injectable medications used to control blood sugar levels in patients with type 2 diabetes. The drugs work by stimulating the release of insulin from the pancreas and suppressing glucagon secretion which helps control blood glucose levels. In addition, these drugs can help with weight loss by reducing appetite.

The global GLP-1 Receptor Agonist Market is estimated to be valued at US$ 11.5 billion in 2023 and is expected to exhibit a CAGR of 17.% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The expanding patient base is one of the key trends driving the growth of the GLP-1 receptor agonist market. The rising prevalence of diabetes globally has boosted the demand for effective diabetes management drugs. As per the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Moreover, obesity is a major risk factor for type 2 diabetes and according to the World Health Organization, nearly 650 million adults are obese worldwide. The dual benefits of blood glucose control as well as weight management offered by GLP-1 receptor agonists have increased their acceptance among diabetic patients with comorbid obesity or overweight conditions.

Segment Analysis


The global GLP-1 receptor agonist market is dominated by the diabetes segment. Within the diabetes segment, the exenatide and liraglutide sub-segments collectively account for over 70% of market share. This is because exenatide and liraglutide were the earliest GLP-1 receptor agonists to be approved for treatment of type 2 diabetes and have demonstrated consistent efficacy in controlling blood sugar levels.

Key Takeaways


The Global GLP-1 Receptor Agonist Market Growth is expected to witness high over the forecast period of 2024 to 2031.

Regional analysis: North America currently dominates the market due to presence of major players and faster uptake of new diabetes drugs in the region. However, Asia Pacific region is expected to grow at the fastest pace during the forecast period supported by rising prevalence of diabetes in countries like China and India.

Key players: Key players operating in the GLP-1 receptor agonist market are Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, Pfizer. Novo Nordisk leads the global GLP-1 receptor agonist market with drugs like Victoza and Ozempic accounting for over 50% global market share. Eli Lilly's Trulicity is another top-selling GLP-1 receptor agonist.

Explore more information on this topic, Please visit-
https://www.marketwebjournal.com/glp-1-receptor-agonist-market-growth-and-trnds-analysis-share-size-demand-forecast-2/ 

Comments

Post a Comment

Popular posts from this blog

Riding the Wave: Navigating Dynamics in the Windsurf Foil Board Market

Image
   Windsurf Foil Board Market In the exhilarating world of water sports, the Windsurf Foil Board Market emerges as a key player, offering enthusiasts innovative equipment to enhance their riding experience. As this niche market continues to gain traction among windsurfing aficionados worldwide, it undergoes significant shifts influenced by various drivers, challenges, and geographical nuances. The Windsurf Foil Board Market size was valued at  US$ 167.4 Mn in 2024  and is expected to reach  US$ 268.6 Mn by 2031 , growing at a compound annual growth rate  (CAGR) of 7% from 2024 to 2031 Key Takeaways A prominent trend in the Windsurf Foil Board Market Demand is the increasing adoption of foil technology. Foil boards, equipped with hydrofoils beneath the waterline, enable riders to glide effortlessly above the water's surface, providing a thrilling and dynamic experience. This technological innovation has revolutionized the windsurfing landscape, attrac...
Read more

Navigating Opportunities In The Niemann-Pick Disease Drug Type C Treatment Market

Image
  Niemann-Pick Disease Drug Type C Treatment Market Key Takeaways The Niemann-Pick Disease Drug Type C Treatment Market is witnessing significant growth, driven by advancements in medical research and a deeper understanding of the disease pathology. Niemann-Pick Disease Type C (NPC) is a rare genetic disorder characterized by the accumulation of cholesterol and other lipids within cells, leading to progressive neurological and visceral symptoms. With an increasing focus on rare diseases and orphan drug development, the market for NPC treatment is expanding rapidly, offering hope to patients and caregivers. Key players in the pharmaceutical industry are actively investing in research and development to bring novel therapies to market, underscoring the potential for transformative interventions in NPC management. Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at  US$ 45.40  million  in 2024, and is expected to exhibit a  CAG...
Read more

Automation of Agricultural Operations to Drive the Agricultural Drones Market Growth

Image
  Agricultural Drones Market The agricultural drones market enables precision farming and monitoring crop health, soil conditions as well as pests and diseases. Agricultural drones carry cameras, sensors or GPS trackers and help in crop monitoring, crop spraying, field mapping as well as aerial imaging. Agricultural drones generate high-resolution images and thermal maps, improving crop scouting and yield predictions. They help farmers optimize inputs, maximize productivity and minimize environmental impact. The global agricultural drones market is estimated to be valued at US$ 19.24 Bn in 2024 and is expected to exhibit a CAGR of 21% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Agricultural Drones Market Size include Aeronavics, AeroVironment Inc., AgEagle Aerial Systems Inc., DELAIR SAS, DRONE VOLT, FlyGuys, Harris Aerial, ideaForge Technologies Pvt. Ltd., Kray Technologies, Nextech, Parrot Drones SAS, PrecisionHawk Inc., Sentera Inc., S...
Read more